Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Mutant Heat Shock Protein Vaccine Prevents Vitiligo in Mouse Model

By BiotechDaily International staff writers
Posted on 11 Mar 2013
Image: Mice that have developed vitiligo (Photo courtesy of Loyola University Chicago Stritch School of Medicine).
Image: Mice that have developed vitiligo (Photo courtesy of Loyola University Chicago Stritch School of Medicine).
Image: Vitiligo mice after vaccination with mutant HSP70i protein (Photo courtesy of Loyola University Chicago Stritch School of Medicine).
Image: Vitiligo mice after vaccination with mutant HSP70i protein (Photo courtesy of Loyola University Chicago Stritch School of Medicine).
An experimental vaccine based on a genetically modified form of inducible heat shock protein 70 (HSP70i) prevented onset and partially cured vitiligo in a mouse model of the disease.

Vitiligo is skin disorder manifested by smooth, white spots on various parts of the body. Though melanocytes, the pigment-making cells of the skin, are structurally intact, they have lost the ability to synthesize the pigment. The reason for the condition is unclear although research suggests that it may arise from autoimmune, genetic, oxidative stress, neural, or viral causes. Individuals with vitiligo (about 1% of the adult population) are usually in good general health, but vitiligo presents a cosmetic problem that can be serious in dark-skinned individuals. Normal skin color rarely returns, and there is no known cure.

Investigators at Loyola University (Chicago, IL, USA) had shown previously that HSP70i played a vital role in the autoimmune response that causes vitiligo. In the current work they genetically modified one of HSP70i's 641 amino acids to create a mutant HSP70i molecule.

The investigators reported in the February 27, 2013, issue of the journal Science Translational Medicine that a vaccine based on the DNA encoding for mutant HSP70i applied months before spontaneous depigmentation prevented vitiligo in mice expressing a transgenic, melanocyte-reactive T-cell receptor. Furthermore, use of mutant HSP70i therapeutically in a different, rapidly depigmenting model after loss of differentiated melanocytes resulted in 76% recovery of pigmentation. Treatment also prevented relevant T-cells from populating mouse skin.

In addition to the dramatic results seen in the mouse model, “The mice look normal,” said senior author Dr. I. Caroline Le Poole, professor of pathology, microbiology, and immunology at Loyola University. Some of the beneficial effects of mutant HSP70i were seen in cultures grown from human vitiligo skin specimens.

Related Links:
Loyola University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A leukemia cell coated with antibody is marked for destruction by activated natural killer cells (Photo courtesy of the University of Southern California).

Leukemia Cells Are Killed in Culture by Immune Cells Grown from the Same Patient

Immune system natural killer (NK) cells were isolated from leukemia patients, expanded in culture, and then shown in an in vitro system to attack and destroy cancer cells from the original cell donors.... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

White-Matter Deficits Found in Codeine-Containing Cough Syrup Users

A magnetic resonance imaging (MRI) study of chronic users of codeine-containing cough syrups (CCS) has found deficits in specific regions of brain white matter and linked these changes with increased impulsivity in codeine-containing cough syrup users. These findings were consistent with findings from earlier research of... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.